Please use this identifier to cite or link to this item:
Title: Amfenac increases the radiosensitivity of uveal melanoma cell lines
Authors: Fernandes, B. F.
Marshall, J-C
Di Cesare, S.
Logan, P.
Maloney, S.
Burnier Júnior, Miguel Noel Nascente [UNIFESP]
McGill Univ
Henry C Witelson Ocular Pathol Lab
Universidade Federal de São Paulo (UNIFESP)
Keywords: uveal melanoma
cell lines
Issue Date: 1-May-2008
Publisher: Nature Publishing Group
Citation: Eye. London: Nature Publishing Group, v. 22, n. 5, p. 701-706, 2008.
Abstract: Purpose To evaluate the proliferation rates of five human uveal melanoma (UM) cell lines after treatment with amfenac, a cyclooxygenase (COX)-2 inhibitor, and subsequent radiation exposure.Methods Five human UM cell lines (92.1, SP6.5, MKT-BR, OCM-1, and UW-1) and one human fibroblast cell line (BJ) were incubated with amfenac. Treated and non-treated cell lines were then exposed to various doses of gamma radiation: 0, 2, 4, 6, and 8 Gy. Sulphorhodamine-B assay was used to assess proliferation rates 48 h post-radiation.Results Treatment of UM cell lines with amfenac prior to radiation led to a marked reduction in proliferation rates. This difference was statistically significant in all cell lines at every radiation dose (P < 0.005), with the exception of 92.1 at 2 Gy (P=0.157). Fibroblasts treated with amfenac showed significantly higher proliferation rates after 2 and 8 Gy, with no significant differences at 0, 4, and 6 Gy.Conclusions the radiosensitivity of UM cell lines was increased by the administration of amfenac, the active metabolite of nepafenac. There appears to be a radioprotective effect of amfenac on human fibroblasts. the topical administration of nepafenac may decrease tumour recurrence and radiation-induced complications while broadening the indications for radiotherapy by treating larger tumours.
ISSN: 0950-222X
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.